When it comes to Alzheimer’s disease, Biogen isn’t putting all of its eggs in the same basket. In the latest development of a multi-drug and multi-disease collaboration, the company has licensed an experimental Ionis Pharmaceuticals compound that works in a different way than the therapies currently in its pipeline for neurodegenerative diseases.

On Thursday, Ionis Pharmaceuticals (NASDAQ: IONS) announced that its Cambridge, MA-based partner (NASDAQ: BIIB) has licensed an experimental Alzheimer’s drug it is testing that’s designed to reduce the production of tau, a protein associated with the increasingly common neurological disorder.

For rights to the experimental tau drug,… Read more »